{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:24:33Z","timestamp":1793143473015,"version":"4.5.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s12325-021-01841-4","type":"journal-article","created":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T04:02:56Z","timestamp":1626062576000},"page":"4178-4194","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Applying State-of-the-Art Survival Extrapolation Techniques to the Evaluation of CAR-T Therapies: Evidence from a Systematic Literature Review"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4360-6278","authenticated-orcid":false,"given":"Matthew","family":"Sussman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Crivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Benner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Adair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,12]]},"reference":[{"key":"1841_CR1","unstructured":"Food & Drug Administration. YESCARTA Prescribing Information. 2020. https:\/\/www.fda.gov\/media\/108377\/download. Accessed 18 Dec 2020."},{"key":"1841_CR2","unstructured":"Food & Drug Administration. KYMRIAH Prescribing Information. 2018. https:\/\/www.fda.gov\/files\/vaccines%2C%20blood%20%26%20biologics\/published\/Package-Insert---KYMRIAH.pdf. Accessed 18 Dec 2020"},{"key":"1841_CR3","unstructured":"Food & Drug Administration. BREYANZI Prescribing Information. 2021. https:\/\/www.fda.gov\/media\/145711\/download. Accessed 30 Mar 2021."},{"key":"1841_CR4","unstructured":"Food & Drug Administration. Tecartus Prescribing Information. 2021. https:\/\/www.fda.gov\/media\/140409\/download. Accessed 30 Mar 2021."},{"key":"1841_CR5","unstructured":"Food & Drug Administration. Abecma Prescribing Information. 2021. https:\/\/www.fda.gov\/media\/147055\/download. Accessed 19 Apr 2021."},{"issue":"Supplement 1","key":"1841_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood-2020-136307","volume":"136","author":"D Madduri","year":"2020","unstructured":"Madduri D, Berdeja JG, Usmani SZ, et al. CARTITUDE-1: phase 1b\/2 study of ciltacabtagene autoleucel, a B\u00a0cell maturation antigen-directed chimeric antigen receptor T\u00a0cell therapy, in relapsed\/refractory multiple myeloma. Blood. 2020;136(Supplement 1):22\u20135.","journal-title":"Blood"},{"issue":"8","key":"1841_CR7","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"key":"1841_CR8","unstructured":"Hildreth C. CAR-T\u00a0cell companies proliferate: list of CAR-T companies worldwide. BioInformant. 2021 Feb 3. https:\/\/bioinformant.com\/car-t-companies-the-meteoric-rise-of-cellular-immunotherapies\/. Accessed 30 Mar 2021."},{"issue":"14","key":"1841_CR9","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1158\/1078-0432.CCR-11-2859","volume":"18","author":"M Othus","year":"2012","unstructured":"Othus M, Barlogie B, LeBlanc ML, Crowley JJ. Cure models as a useful statistical tool for analyzing survival. Clin Cancer Res. 2012;18(14):3731\u20136.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1841_CR10","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1093\/biostatistics\/kxl030","volume":"8","author":"PC Lambert","year":"2007","unstructured":"Lambert PC, Thompson JR, Weston CL, Dickman PW. Estimating and modeling the cure fraction in population-based cancer survival analysis. Biostatistics. 2007;8(3):576\u201394.","journal-title":"Biostatistics"},{"issue":"4","key":"1841_CR11","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1177\/1536867X1201200404","volume":"12","author":"TM-L Andersson","year":"2012","unstructured":"Andersson TM-L, Lambert PC. Fitting and modeling cure in population-based cancer studies within the framework of flexible parametric survival models. Stata J. 2012;12(4):623\u201338.","journal-title":"Stata J"},{"key":"1841_CR12","unstructured":"Woods B, Sideris E, Palmer S, Latimer N, Soares M. NICE DSU technical support document 19: partitioned survival analysis for decision modelling in health care: a critical review report by the decision support unit. 2017. Available from http:\/\/www.nicedsu.org.uk."},{"issue":"4","key":"1841_CR13","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jval.2016.04.011","volume":"20","author":"M Othus","year":"2017","unstructured":"Othus M, Bansal A, Koepl L, Wagner S, Ramsey S. Accounting for cured patients in cost-effectiveness analysis. Value Health. 2017;20(4):705\u20139.","journal-title":"Value Health"},{"issue":"1","key":"1841_CR14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.2517-6161.1949.tb00020.x","volume":"11","author":"JW Boag","year":"1949","unstructured":"Boag JW. Maximum likelihood estimates of the proportion of patients cured by cancer therapy. J R Stat Soc Ser B Methodol. 1949;11(1):15\u201353.","journal-title":"J R Stat Soc Ser B Methodol"},{"issue":"464","key":"1841_CR15","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1198\/01622145030000001007","volume":"98","author":"AD Tsodikov","year":"2003","unstructured":"Tsodikov AD, Ibrahim JG, Yakovlev AY. Estimating cure rates from survival data: an alternative to two-component mixture models. J Am Stat Assoc. 2003;98(464):1063\u201378.","journal-title":"J Am Stat Assoc"},{"key":"1841_CR16","unstructured":"Yakovlev A, Asselain B, Bardou V, et al. A simple stochastic model of tumor recurrence and its applications to data on pre-menopausal breast cancer. In: Biometrics and analysis dormees spatio\u2013temporal. Rennes: French Society of Biometrics; 1993."},{"issue":"2","key":"1841_CR17","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1177\/1536867X0900900206","volume":"9","author":"PC Lambert","year":"2009","unstructured":"Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. Stata J Promot Commun Stat Stata. 2009;9(2):265\u201390.","journal-title":"Stata J Promot Commun Stat Stata"},{"issue":"30","key":"1841_CR18","doi-asserted-by":"publisher","first-page":"5486","DOI":"10.1002\/sim.3064","volume":"26","author":"CP Nelson","year":"2007","unstructured":"Nelson CP, Lambert PC, Squire IB, Jones DR. Flexible parametric models for relative survival, with application in coronary heart disease. Stat Med. 2007;26(30):5486\u201398.","journal-title":"Stat Med"},{"issue":"2","key":"1841_CR19","doi-asserted-by":"publisher","first-page":"e190035","DOI":"10.1001\/jamanetworkopen.2019.0035","volume":"2","author":"MD Whittington","year":"2019","unstructured":"Whittington MD, McQueen RB, Ollendorf DA, et al. Long-term survival and cost-effectiveness associated with axicabtagene ciloleucel vs chemotherapy for treatment of B\u00a0cell lymphoma. JAMA Netw Open. 2019;2(2):e190035.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"1841_CR20","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/0272989X18820535","volume":"39","author":"A Bansal","year":"2019","unstructured":"Bansal A, Sullivan SD, Lin VW, et al. Estimating long-term survival for patients with relapsed or refractory large B\u00a0cell lymphoma treated with chimeric antigen receptor therapy: a comparison of standard and mixture cure models. Med Decis Mak. 2019;39(3):294\u20138.","journal-title":"Med Decis Mak"},{"key":"1841_CR21","doi-asserted-by":"crossref","unstructured":"Kasle A, Qu T, Meng Y. Review and comparison of overall survival extrapolation in health technology assessments CAR-T therapies. In: ISPOR. Orlando, FL, USA; 2020. https:\/\/www.ispor.org\/docs\/default-source\/intl2020\/icer-nice-os-methodspbi36-pdf.pdf?sfvrsn=f27cfaea_0. Accessed 16 Apr 2021.","DOI":"10.1016\/j.jval.2020.04.100"},{"key":"1841_CR22","unstructured":"Kroep S, Kiff C, Kraan C, Bianco M. Modelling the survival benefit of immuno-oncologic therapy: a review of methods used in NICE single technology appraisals. In: ISPOR Europe. Copenhagen, Denmark; 2019. https:\/\/www.pharmerit.com\/wp-content\/uploads\/2019\/11\/MODELING-THE-SURVIVAL-BENEFIT-OF-IMMUNO-ONCOLOGIC-THERAPY-A-REVIEW-OF-METHODS-USED-IN-NICE-SINGLE-TECHNOLOGY-APPRAISALS.pdf. Accessed 16 Apr 2021."},{"issue":"9","key":"1841_CR23","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3389\/fonc.2019.00453","volume":"4","author":"V Damuzzo","year":"2019","unstructured":"Damuzzo V, Agnoletto L, Leonardi L, Chiumente M, Mengato D, Messori A. Analysis of survival curves: statistical methods accounting for the presence of long-term survivors. Front Oncol. 2019;4(9):453.","journal-title":"Front Oncol"},{"key":"1841_CR24","doi-asserted-by":"publisher","first-page":"S377","DOI":"10.1016\/j.jval.2018.09.2246","volume":"21","author":"S Ramsey","year":"2018","unstructured":"Ramsey S, Othus M, Roth J, Yuan Y, Wagner S, Penrod J. PRM126\u2014a comparison of mixture cure and standard parametric modeling to estimate long-term survival for small-cell lung cancer in patients treated with nivolumab after progression. Value Health. 2018;21:S377.","journal-title":"Value Health"},{"key":"1841_CR25","unstructured":"Nukala U, Messan MR, Yogurtcu ON, Wang X, Yang H. A systematic review of the efforts and hindrances of modeling and simulation of CAR T\u00a0cell therapy. ArXiv210105359 Q-Bio. 2021 Mar 2. http:\/\/arxiv.org\/abs\/2101.05359. Accessed 16 Apr 2021."},{"key":"1841_CR26","doi-asserted-by":"publisher","first-page":"S475","DOI":"10.1016\/j.jval.2019.09.401","volume":"22","author":"A Foix Colonier","year":"2019","unstructured":"Foix Colonier A, Genestier V, Lueza B. PCN205 comparison of methods to account for cured patients in a cost-effectiveness analysis: a case study in oncology. Value Health. 2019;22:S475.","journal-title":"Value Health"},{"key":"1841_CR27","unstructured":"Porteous A, van Hest N, Griffiths M, Morten P. Exploring the use and acceptance of alternative survival modelling approaches for immuno\u2013oncology therapies in UK Technology Assessments. In: ISPOR Europe. Barcelona, Spain; 2018. https:\/\/www.costellomedical.com\/wp-content\/uploads\/2018\/11\/Survival-Modelling.pdf. Accessed 16 Apr 2021."},{"key":"1841_CR28","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.1016\/j.jval.2020.04.1757","volume":"23","author":"M Cooper","year":"2020","unstructured":"Cooper M, Smith S, Williams T, Harding T, Aguiar-Ib\u00e1\u00f1ez R. PCN293 how successful are standard and flexible extrapolation methods for the long-term projection of overall survival compared to trial data subsequently made available for cancer immunotherapies? Value Health. 2020;23:S75.","journal-title":"Value Health"},{"issue":"1","key":"1841_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12874-020-00997-x","volume":"20","author":"A Bullement","year":"2020","unstructured":"Bullement A, Willis A, Amin A, Schlichting M, Hatswell AJ, Bharmal M. Evaluation of survival extrapolation in immuno\u2013oncology using multiple pre-planned data cuts: learnings to aid in model selection. BMC Med Res Methodol. 2020;20(1):103.","journal-title":"BMC Med Res Methodol"},{"issue":"9","key":"1841_CR30","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s40273-019-00806-4","volume":"37","author":"MJNM Ouwens","year":"2019","unstructured":"Ouwens MJNM, Mukhopadhyay P, Zhang Y, Huang M, Latimer N, Briggs A. Estimating lifetime benefits associated with immuno\u2013oncology therapies: challenges and approaches for overall survival extrapolations. Pharmacoeconomics. 2019;37(9):1129\u201338.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"1841_CR31","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1177\/0272989X20978958","volume":"41","author":"J Gray","year":"2021","unstructured":"Gray J, Sullivan T, Latimer NR, et al. Extrapolation of survival curves using standard parametric models and flexible parametric spline models: comparisons in large registry cohorts with advanced cancer. Med Decis Mak. 2021;41(2):179\u201393.","journal-title":"Med Decis Mak"},{"issue":"7","key":"1841_CR32","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group TP. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med"},{"issue":"2","key":"1841_CR33","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jval.2013.02.010","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. Value Health. 2013;16(2):e1-5.","journal-title":"Value Health"},{"issue":"24","key":"1841_CR34","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.18.02079","volume":"37","author":"JK Lin","year":"2019","unstructured":"Lin JK, Muffly LS, Spinner MA, Barnes JI, Owens DK, Goldhaber-Fiebert JD. Cost effectiveness of chimeric antigen receptor T\u00a0cell therapy in multiply relapsed or refractory adult large B\u00a0cell lymphoma. J Clin Oncol. 2019;37(24):2105\u201319.","journal-title":"J Clin Oncol"},{"key":"1841_CR35","unstructured":"Institute for Clinical and Economic Review. Chimeric antigen receptor T cell therapy for B cell cancers: effectiveness and value. 2018. https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_CAR_T_Final_Evidence_Report_032318.pdf. Accessed 8 Jul 2021."},{"issue":"12","key":"1841_CR36","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1001\/jamapediatrics.2018.2530","volume":"172","author":"MD Whittington","year":"2018","unstructured":"Whittington MD, McQueen RB, Ollendorf DA, et al. Long-term survival and value of chimeric antigen receptor T\u00a0cell therapy for pediatric patients with relapsed or refractory leukemia. JAMA Pediatr. 2018;172(12):1161.","journal-title":"JAMA Pediatr"},{"issue":"32","key":"1841_CR37","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1200\/JCO.2018.79.0642","volume":"36","author":"JK Lin","year":"2018","unstructured":"Lin JK, Lerman BJ, Barnes JI, et al. Cost Effectiveness of chimeric antigen receptor T\u00a0cell therapy in relapsed or refractory pediatric B\u00a0cell acute lymphoblastic leukemia. J Clin Oncol. 2018;36(32):3192\u2013202.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1841_CR38","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1080\/13696998.2018.1529674","volume":"21","author":"JA Roth","year":"2018","unstructured":"Roth JA, Sullivan SD, Lin VW, et al. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B\u00a0cell lymphoma in the United States. J Med Econ. 2018;21(12):1238\u201345.","journal-title":"J Med Econ"},{"issue":"7","key":"1841_CR39","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/jnci\/djy193","volume":"111","author":"RR Sarkar","year":"2019","unstructured":"Sarkar RR, Gloude NJ, Schiff D, Murphy JD. Cost-effectiveness of chimeric antigen receptor T\u00a0cell therapy in pediatric relapsed\/refractory B\u00a0cell acute lymphoblastic leukemia. J Natl Cancer Inst. 2019;111(7):719\u201326.","journal-title":"J Natl Cancer Inst"},{"key":"1841_CR40","unstructured":"Liu R, Snider T, Diakite I, Tempeleear S, Botteman M. Cost effectiveness of axicabtagene ciloleucel (AXI-CEL) and tisagenlecleucel (TISA-CEL) for adult patients with relapsed or refractory large B\u00a0cell lymphoma (RR LBCL) in the US. In: Virtual European Hematology Association Congress. 2020."},{"key":"1841_CR41","volume-title":"Tisagenlecleucel-T for treating relapsed or refractory B\u00a0cell acute lymphoblastic leukaemia in people aged up to 25 years","author":"M Walton","year":"2018","unstructured":"Walton M, Sharif S, Hodgson R, Claxton L. Tisagenlecleucel-T for treating relapsed or refractory B\u00a0cell acute lymphoblastic leukaemia in people aged up to 25 years. National Institute for Health and Care Excellence; 2018."},{"key":"1841_CR42","volume-title":"Axicabtagene ciloleucel for treating diffuse large B\u00a0cell lymphoma and primary mediastinal B\u00a0cell lymphoma after 2 or more systemic therapies [ID1115]","author":"National Institute for Health and Care Excellence","year":"2018","unstructured":"National Institute for Health and Care Excellence. Axicabtagene ciloleucel for treating diffuse large B\u00a0cell lymphoma and primary mediastinal B\u00a0cell lymphoma after 2 or more systemic therapies [ID1115]. National Institute for Health and Care Excellence; 2018."},{"key":"1841_CR43","volume-title":"Tisagenlecleucel for treating relapsed or refractory diffuse large B\u00a0cell lymphoma","author":"M Corbett","year":"2018","unstructured":"Corbett M, Duarte A, Walker S, Wright K. Tisagenlecleucel for treating relapsed or refractory diffuse large B\u00a0cell lymphoma. National Institute for Health and Care Excellence; 2018."},{"issue":"3","key":"1841_CR44","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1001\/jamaoncol.2019.5909","volume":"6","author":"J Furzer","year":"2020","unstructured":"Furzer J, Gupta S, Nathan PC, et al. Cost-effectiveness of tisagenlecleucel vs standard care in high-risk relapsed pediatric acute lymphoblastic leukemia in Canada. JAMA Oncol. 2020;6(3):393.","journal-title":"JAMA Oncol"},{"key":"1841_CR45","unstructured":"Canadian Agency for Drugs and Technologies in Health. Axicabtagene ciloleucel for diffuse large B cell lymphoma: economic review report. 2019. https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/car-t\/ct0002-axicabtagene-ciloleucel-economic-report-redacted.pdf. Accessed 8 Jul 2021."},{"key":"1841_CR46","unstructured":"Canadian Agency for Drugs and Technologies in Health. Tisagenlecleucel for diffuse large B cell lymphoma: economic review report. 2019. https:\/\/cadth.ca\/sites\/default\/files\/pdf\/car-t\/op0538-tisagenlecleucel-economic-report-DLBCL-jan2019.pdf. Accessed 8 Jul 2021."},{"key":"1841_CR47","unstructured":"Medical Services Advisory Committee. Tisagenlecleucel (CTL019) for treatment of refractory CD19-positive leukaemia and lymphoma: Public Summary Document. 2019. http:\/\/www.msac.gov.au\/internet\/msac\/publishing.nsf\/Content\/BE2E1EB50ED57442CA2581F4000C1723\/$File\/1519-Final%20PSD-April%202019_redacted.pdf. Accessed 8 Jul 2021."},{"key":"1841_CR48","unstructured":"Medical Services Advisory Committee. Axicabtagene ciloleucel (CAR-T therapy) for the treatment of refractory or relapsed CD19-positive lymphoma: Public Summary Document. 2020. http:\/\/www.msac.gov.au\/internet\/msac\/publishing.nsf\/Content\/B5B780278B3A4B48CA2583C9001B80BB\/$File\/1587%20Final%20PSD%20Nov%2019_redacted.pdf. Accessed 8 Jul 2021."},{"key":"1841_CR49","unstructured":"Medical Services Advisory Committee. Tisagenlecleucel (CTL019) for treatment of relapsed or refractory diffuse large B cell lymphoma (DLBCL): Public Summary Document. 2019. http:\/\/www.msac.gov.au\/internet\/msac\/publishing.nsf\/Content\/A2B10F9A03293BC8CA2583CF001C7A4D\/$File\/1519.1%20Final%20updated%20PSD%20Nov%2019_redacted.pdf. Accessed 8 Jul 2021."},{"key":"1841_CR50","first-page":"253","volume":"12","author":"JM Ribera Santasusana","year":"2020","unstructured":"Ribera Santasusana JM, de Andr\u00e9s Salda\u00f1a A, Garc\u00eda-Mu\u00f1oz N, Gostkorzewicz J, Mart\u00ednez Llin\u00e0s D, D\u00edaz-de-Heredia C. Cost-effectiveness analysis of tisagenlecleucel in the treatment of relapsed or refractory B\u00a0cell acute lymphoblastic leukaemia in children and young adults in Spain. Clin Outcomes Res CEOR. 2020;12:253\u201364.","journal-title":"Clin Outcomes Res CEOR"},{"key":"1841_CR51","unstructured":"Sierra J, Briones J, Calleja A, Camacho C. Axicabtagene ciloleucel for the management of patients with diffuse large B\u00a0cell lymphoma and primary mediastinal large B\u00a0cell lymphoma: an economic evaluation for Spain. In: Virtual European Hematology Association Congress. 2020."},{"issue":"2","key":"1841_CR52","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/ejh.13427","volume":"105","author":"FW Thielen","year":"2020","unstructured":"Thielen FW, Dongen-Leunis A, Arons AMM, Ladestein JR, Hoogerbrugge PM, Uyl-de Groot CA. Cost-effectiveness of anti-CD19 chimeric antigen receptor T\u00a0cell therapy in pediatric relapsed\/refractory B\u00a0cell acute lymphoblastic leukemia. A societal view. Eur J Haematol. 2020;105(2):203\u201315.","journal-title":"Eur J Haematol"},{"issue":"Supplement 1","key":"1841_CR53","doi-asserted-by":"publisher","first-page":"4779","DOI":"10.1182\/blood-2018-99-113838","volume":"132","author":"M Marchetti","year":"2018","unstructured":"Marchetti M, Martelli E, Zinzani PL. Cost-effectiveness of axicabtagene ciloleucel for relapsed or refractory dffuse large B\u00a0cell lymphoma in Italy. Blood. 2018;132(Supplement 1):4779\u20134779.","journal-title":"Blood"},{"key":"1841_CR54","doi-asserted-by":"publisher","first-page":"S687","DOI":"10.1016\/j.jval.2020.08.1720","volume":"23","author":"K Karampampa","year":"2020","unstructured":"Karampampa K, Stene E, Axelsen F, et al. PPM3 cost-effectiveness of axicabtagene ciloleucel (AXI-CEL) vs standard of care for adult patients with relapsed or refractory diffuse large B\u00a0cell lymphoma in Sweden, Norway, Finland, and Denmark. Value Health. 2020;23:S687.","journal-title":"Value Health"},{"issue":"1","key":"1841_CR55","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B\u00a0cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20(1):31\u201342.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1841_CR56","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B\u00a0cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"key":"1841_CR57","unstructured":"Novartis Pharmaceuticals. Study of efficacy and safety of CTL019 in pediatric all patients (ENSIGN). Clinicaltrials.com; 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02228096. Accessed 16 Apr 2021."},{"issue":"26","key":"1841_CR58","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T\u00a0cells in refractory B\u00a0cell lymphomas. N Engl J Med. 2017;377(26):2545\u201354.","journal-title":"N Engl J Med"},{"issue":"2","key":"1841_CR59","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1467-985X.2008.00573.x","volume":"172","author":"CH Jackson","year":"2009","unstructured":"Jackson CH, Thompson SG, Sharples LD. Accounting for uncertainty in health economic decision models by using model averaging. J R Stat Soc Ser A Stat Soc. 2009;172(2):383\u2013404.","journal-title":"J R Stat Soc Ser A Stat Soc"},{"issue":"Supp1","key":"1841_CR60","first-page":"609","volume":"130","author":"Y Hao","year":"2017","unstructured":"Hao Y, Eldjerou L, Yang H, Qi C, Globe D. Cost-effectiveness analysis of CTL019 for the treatment of pediatric and young adult patients with relapsed or refractory B\u00a0cell acute lymphoblastic leukemia in the United States. Blood. 2017;130(Supp1):609.","journal-title":"Blood"},{"key":"1841_CR61","unstructured":"Kattamis A, Avgitidou A, Chatzopoulos S, Markouri A. Cost-effectiveness of tisagenlecleucel in paediatric and young adult relapsed or refractory B cell acute lymphobastic leukaemia, from a Greek social security system perspective. In: ISPOR EU. Copenhagen, Denmark; 2019. https:\/\/www.ispor.org\/heor-resources\/presentations-database\/presentation\/euro2019-3119\/97419. Accessed 16 Apr 2021."},{"key":"1841_CR62","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/j.jval.2018.09.260","volume":"21","author":"H Yang","year":"2018","unstructured":"Yang H, Qi C, Zhang J, El Ouagari K. Cost-effectiveness of tisagenlecleucel for adults with relapsed or refractory diffuse large B\u00a0cell lymphoma: a Canadian societal perspective. Value Health. 2018;21:S44.","journal-title":"Value Health"},{"key":"1841_CR63","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/j.jval.2018.09.253","volume":"21","author":"H Yang","year":"2018","unstructured":"Yang H, Zhang J, Hampe M. Cost-effectiveness of tisagenlecleucel in pediatric and young adult patients with relapsed or refractory B\u00a0cell acute lymphoblastic leukemia: a Canadian societal perspective. Value Health. 2018;21:S43.","journal-title":"Value Health"},{"issue":"12","key":"1841_CR64","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s40273-017-0558-5","volume":"35","author":"E Gibson","year":"2017","unstructured":"Gibson E, Koblbauer I, Begum N, et al. Modelling the survival outcomes of immuno\u2013oncology drugs in economic evaluations: a systematic approach to data analysis and extrapolation. Pharmacoeconomics. 2017;35(12):1257\u201370.","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"1841_CR65","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jval.2018.10.007","volume":"22","author":"A Bullement","year":"2019","unstructured":"Bullement A, Latimer NR, Bell GH. Survival extrapolation in cancer immunotherapy: a validation-based case study. Value Health. 2019;22(3):276\u201383.","journal-title":"Value Health"},{"issue":"Supplement 1","key":"1841_CR66","first-page":"40","volume":"136","author":"C Jacobson","year":"2020","unstructured":"Jacobson C, Locke FL, Ghobadi A, et al. Long-term survival and gradual recovery of B\u00a0cells in patients with refractory large B\u00a0cell lymphoma treated with axicabtagene ciloleucel (Axi-Cel). Blood. 2020;136(Supplement 1):40\u20132.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1841_CR67","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1182\/blood-2020-137045","volume":"136","author":"U Jaeger","year":"2020","unstructured":"Jaeger U, Bishop MR, Salles G, et al. Myc expression and tumor-infiltrating T\u00a0cells are associated with response in patients (Pts) with relapsed\/refractory diffuse large B\u00a0cell lymphoma (r\/r DLBCL) treated with tisagenlecleucel in the Juliet Trial. Blood. 2020;136(Supplement 1):48\u20139.","journal-title":"Blood"},{"key":"1841_CR68","unstructured":"Fitzgerald L, Kittai S, Nastoupil L, Waller A. Real world outcomes of elderly patients with relapsed\/refractory diffuse large B cell lymphoma treated with chimeric antigen receptor T\u00a0cell therapy: an updated analysis. In: 62nd ASH Annual Meeting & Exposition. Virtual; 2020. https:\/\/ash.confex.com\/ash\/2020\/webprogram\/Paper143236.html. Accessed 19 Apr 2021."},{"issue":"Supplement 1","key":"1841_CR69","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1182\/blood-2020-143348","volume":"136","author":"EA Chong","year":"2020","unstructured":"Chong EA, Chong ER, Landsburg DJ, et al. Anti-CD19 CAR-T for treatment of double expressor and double hit large B\u00a0cell lymphomas: a single institution real-world analysis. Blood. 2020;136(Supplement 1):19\u201320.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1841_CR70","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1182\/blood-2020-142932","volume":"136","author":"V Buecklein","year":"2020","unstructured":"Buecklein V, Blumenberg V, Ackermann J, et al. Single-center experience with axicabtagene-ciloleucel (Axi-cel) and tisagenlecleucel (Tisa-cel) for relapsed\/refractory diffuse large B\u00a0cell lymphoma: comparable response rates and manageable toxicity. Blood. 2020;136(Supplement 1):34\u20135.","journal-title":"Blood"},{"issue":"21","key":"1841_CR71","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","volume":"4","author":"MC Pasquini","year":"2020","unstructured":"Pasquini MC, Hu Z-H, Curran K, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4(21):5414\u201324.","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"1841_CR72","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1182\/blood-2019-130983","volume":"134","author":"S Jaglowski","year":"2019","unstructured":"Jaglowski S, Hu Z-H, Zhang Y, et al. Tisagenlecleucel chimeric antigen receptor (CAR) T\u00a0cell therapy for adults with diffuse large B\u00a0cell lymphoma (DLBCL): real world experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry. Blood. 2019;134(Supplement 1):766\u2013766.","journal-title":"Blood"},{"issue":"27","key":"1841_CR73","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B\u00a0cell lymphoma: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2020;38(27):3119\u201328.","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"1841_CR74","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1182\/blood-2020-136201","volume":"136","author":"G Iacoboni","year":"2020","unstructured":"Iacoboni G, Iraola-Truchuelo J, Martinez-Cibrian N, et al. Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B\u00a0cell lymphoma. Blood. 2020;136(Supplement 1):19\u201321.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1841_CR75","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1182\/blood-2019-127490","volume":"134","author":"PA Riedell","year":"2019","unstructured":"Riedell PA, Walling C, Nastoupil LJ, et al. A multicenter retrospective analysis of clinical outcomes, toxicities, and patterns of use in institutions utilizing commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B\u00a0cell lymphomas. Blood. 2019;134(Supplement 1):1599\u20131599.","journal-title":"Blood"},{"issue":"4","key":"1841_CR76","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s40273-019-00867-5","volume":"38","author":"TS Grant","year":"2020","unstructured":"Grant TS, Burns D, Kiff C, Lee D. A case study examining the usefulness of cure modelling for the prediction of survival based on data maturity. Pharmacoeconomics. 2020;38(4):385\u201395.","journal-title":"Pharmacoeconomics"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01841-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01841-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01841-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T22:20:30Z","timestamp":1725402030000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01841-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,12]]},"references-count":76,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1841"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01841-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,12]]},"assertion":[{"value":"6 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}